Atlas Trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

Clinical trial NCT05052697 · COMPLETED

Trial details

NCT number
NCT05052697
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Influenza, Human
Start date
2021-09-13
Primary completion
2023-01-27
Enrollment
1158

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.